GLPwatch

Observational Study of Interstitial Glucose Monitoring With Continuous Glucose Monitoring to Track Patients Treated With Exenatide

NCT00569907 · Completed

Last updated 2026-05-28

This study tracks how well a wearable glucose monitor works in adults with type 2 diabetes who are using the diabetes medication exenatide.

Status Completed The study has finished.
Type Observational
Participants 18 people
Who can join Ages 21+ · all sexes
Timeline Started 2007-01 · est. completion 2009-05
Where 1 site · United States

What this study is testing ClinicalTrials.gov NCT00569907 ↗

Description as written by the study sponsor.

Approximately 30 adults will participate in this study at the International Diabetes Center (IDC). The IDC is the only site conducting this study. Length of participation can range from two to three months which will include four to seven clinic visits. The purpose of this study is to use a Continuous Glucose Monitoring (CGM) system to determine the characteristics of glucose control and patterns of food intake before exenatide is started, during the start and adjustment of exenatide and during exenatide treatment. The long-term purpose of this study is to determine to what extent continuous glucose monitoring improves or alters clinical decision making for patients treated with exenatide. And, the study will also compare CGM to conventional self-monitored blood glucose methods. The study will also compare subjects' changes, if any, in nutrient intake such as energy, protein, fat and carbohydrate during the course of the study through interpretation/analysis of self-reported food intake.

SponsorHealthPartners Institute
Conditions studiedDiabetes Mellitus Type 2
GLP-1 drugs exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT00569907 ↗